<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40975124</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-4738</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of cardiology</Title><ISOAbbreviation>J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Daprodustat for patients with heart failure and renal Anemia: A pilot multicenter, open-label, randomized controlled study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0914-5087(25)00241-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jjcc.2025.09.011</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anemia and renal failure, common comorbidities in patients with heart failure (HF), are associated with increased mortality. Hypoxia-inducible factor prolyl hydroxylase inhibitors, such as daprodustat, treat renal anemia by stimulating erythropoiesis and enhancing iron availability. However, its efficacy in treating HF with renal anemia remains to be determined.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This pilot, multicenter, open-label, randomized controlled trial was conducted in five hospitals in Japan. Patients with HF, anemia (hemoglobin, 7.5-11&#x202f;g/dL), and renal impairment (estimated glomerular filtration rate, &lt;60&#x202f;mL/min/1.73&#x202f;m<sup>2</sup>) not requiring hemodialysis were randomized 1:1 to receive daprodustat or standard of care. The primary endpoint was the hemoglobin level at 16&#x202f;weeks. The secondary endpoints included blood transfusion rates, alleviation of HF symptoms, changes in N-terminal pro-B-type natriuretic peptide and iron-related biomarkers, and cardiac structural and functional changes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-one patients were randomized between March 2022 and November 2023. At 16&#x202f;weeks, the mean hemoglobin level was significantly higher in the daprodustat group (12.1&#x202f;&#xb1;&#x202f;0.73&#x202f;g/dL) than in the standard of care group (10.3&#x202f;&#xb1;&#x202f;0.97&#x202f;g/dL, p&#x202f;&lt;&#x202f;0.001). Serum iron, ferritin, hepcidin, and transferrin saturation levels were significantly lower, whereas N-terminal pro-B-type natriuretic peptide levels were significantly higher in the daprodustat treatment group. Kansas City Cardiomyopathy Questionnaire Total Symptom Score improvement (44.4&#x202f;% vs. 55.6&#x202f;%, p&#x202f;=&#x202f;0.99) and structural and functional cardiac parameters showed no significant differences.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Daprodustat effectively increases hemoglobin levels and modifies iron metabolism by decreasing hepcidin levels and increasing iron utilization in patients with HF and renal anemia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Yu Suresvar</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsue</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. Electronic address: yuya8950@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iso</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujimoto</LastName><ForeName>Yudai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanagisawa</LastName><ForeName>Naotake</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Technology Innovation Center, Juntendo University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shitara</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwa</LastName><ForeName>Satoru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyakuni</LastName><ForeName>Shota</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Kameda Medical Center, Kamogawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizukami</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Kameda Medical Center, Kamogawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okumura</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takasu</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Juntendo University Urayasu Hospital, Urayasu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokano</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Juntendo University Urayasu Hospital, Urayasu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiki</LastName><ForeName>Masaru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Juntendo University Nerima Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isoda</LastName><ForeName>Kikuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Juntendo University Nerima Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyauchi</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minamino</LastName><ForeName>Tohru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan; Japan Agency for Medical Research and Development-Core Research for Evolutionary Medical Science and Technology (AMED-CREST), Japan Agency for Medical Research and Development, Tokyo, Japan. Electronic address: t.minamino@juntendo.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Cardiol</MedlineTA><NlmUniqueID>8804703</NlmUniqueID><ISSNLinking>0914-5087</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Daprodustat</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Hypoxia-inducible factor prolyl hydroxylase inhibitors</Keyword><Keyword MajorTopicYN="N">Iron metabolism</Keyword><Keyword MajorTopicYN="N">Renal anemia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>19</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40975124</ArticleId><ArticleId IdType="doi">10.1016/j.jjcc.2025.09.011</ArticleId><ArticleId IdType="pii">S0914-5087(25)00241-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>